Literature DB >> 27468087

Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.

Preetesh Jain1, Rashmi Kanagal-Shamanna2, William Wierda1, Michael Keating1, Nawid Sarwari1, Uri Rozovski1, Philip Thompson1, Jan Burger1, Hagop Kantarjian1, Keyur P Patel2, L Jeffrey Medeiros2, Rajyalakshmi Luthra2, Zeev Estrov3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27468087      PMCID： PMC5073031          DOI： 10.1002/ajh.24496

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  10 in total

1.  Evidence for a role of CRM1 in signal-mediated nuclear protein export.

Authors:  B Ossareh-Nazari; F Bachelerie; C Dargemont
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

2.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

3.  CRM1 is an export receptor for leucine-rich nuclear export signals.

Authors:  M Fornerod; M Ohno; M Yoshida; I W Mattaj
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

4.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Valeria Spina; Alessio Bruscaggin; Sara Monti; Carmela Ciardullo; Clara Deambrogi; Hossein Khiabanian; Roberto Serra; Francesco Bertoni; Francesco Forconi; Luca Laurenti; Roberto Marasca; Michele Dal-Bo; Francesca Maria Rossi; Pietro Bulian; Josep Nomdedeu; Giovanni Del Poeta; Valter Gattei; Laura Pasqualucci; Raul Rabadan; Robin Foà; Riccardo Dalla-Favera; Gianluca Gaidano
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

Review 5.  Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Authors:  Joel G Turner; Jana Dawson; Christopher L Cubitt; Rachid Baz; Daniel M Sullivan
Journal:  Semin Cancer Biol       Date:  2014-03-12       Impact factor: 15.707

6.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

7.  STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.

Authors:  Inbal Hazan-Halevy; David Harris; Zhiming Liu; Jie Liu; Ping Li; Xiaomin Chen; Sreejesh Shanker; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

8.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

9.  NESdb: a database of NES-containing CRM1 cargoes.

Authors:  Darui Xu; Nick V Grishin; Yuh Min Chook
Journal:  Mol Biol Cell       Date:  2012-07-25       Impact factor: 4.138

10.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528
  10 in total
  9 in total

Review 1.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

Review 2.  Karyopherin-mediated nucleocytoplasmic transport.

Authors:  Casey E Wing; Ho Yee Joyce Fung; Yuh Min Chook
Journal:  Nat Rev Mol Cell Biol       Date:  2022-01-20       Impact factor: 113.915

Review 3.  XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.

Authors:  Vincent Camus; Hadjer Miloudi; Antoine Taly; Brigitte Sola; Fabrice Jardin
Journal:  J Hematol Oncol       Date:  2017-02-14       Impact factor: 17.388

4.  Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.

Authors:  Jasper Edgar Neggers; Els Vanstreels; Erkan Baloglu; Sharon Shacham; Yosef Landesman; Dirk Daelemans
Journal:  Oncotarget       Date:  2016-10-18

5.  KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib.

Authors:  Danian Nie; Kezhi Huang; Songmei Yin; Yiqing Li; Shuangfeng Xie; Liping Ma; Xiuju Wang; Yudan Wu; Jie Xiao; Jieyu Wang; Wenjuan Yang; Hongyun Liu
Journal:  Cell Death Discov       Date:  2018-04-23

6.  XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma.

Authors:  David Jérémie Birnbaum; Pascal Finetti; Daniel Birnbaum; Emilie Mamessier; François Bertucci
Journal:  J Clin Med       Date:  2019-04-30       Impact factor: 4.241

7.  Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.

Authors:  Janek S Walker; Zachary A Hing; Bonnie Harrington; Jordan Baumhardt; Hatice Gulcin Ozer; Amy Lehman; Brian Giacopelli; Larry Beaver; Katie Williams; Jordan N Skinner; Casey B Cempre; Qingxiang Sun; Sharon Shacham; Benjamin R Stromberg; Matthew K Summers; Lynne V Abruzzo; Laura Rassenti; Thomas J Kipps; Sameer Parikh; Neil E Kay; Kerry A Rogers; Jennifer A Woyach; Vincenzo Coppola; Yuh Min Chook; Christopher Oakes; John C Byrd; Rosa Lapalombella
Journal:  J Hematol Oncol       Date:  2021-01-15       Impact factor: 23.168

Review 8.  NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.

Authors:  Emanuela Rosati; Stefano Baldoni; Filomena De Falco; Beatrice Del Papa; Erica Dorillo; Chiara Rompietti; Elisa Albi; Franca Falzetti; Mauro Di Ianni; Paolo Sportoletti
Journal:  Front Oncol       Date:  2018-06-27       Impact factor: 6.244

Review 9.  Therapeutic Targeting of Exportin-1 in Childhood Cancer.

Authors:  Basia Galinski; Thomas B Alexander; Daniel A Mitchell; Hannah V Chatwin; Chidiebere Awah; Adam L Green; Daniel A Weiser
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.